The DOI matches its Crossref record; the references it cites are not checked yet.
Maternal perspectives on the RSV vaccine (Abrysvo): a thematic analysis of survey findings from the first season of implementation in England and Scotland
Abstract
Background: Respiratory syncytial virus (RSV) is a leading cause of infant hospitalisation due to lower respiratory tract infections. Until 2022, prevention was limited to the costly monoclonal antibody palivizumab. In August 2024, the UK introduced the RSVpreF (Abrysvo, Pfizer) maternal vaccine into its national immunisation schedule. The success of this programme depends not only on vaccine effectiveness, but also on maternal access, acceptance and uptake. Objective: To explore maternal perspectives on the RSVpreF vaccine and identify barriers and facilitators to vaccine uptake, to inform antenatal education and public health strategies. Methods: This qualitative analysis is based on free-text survey responses from 388 vaccine-eligible mothers of infants hospitalised with bronchiolitis, lower respiratory tract infection or acute wheeze, collected between September 2024 and March 2025 across 30 sites, as part of the BronchStop study. Results: Four key themes were identified: (1) access-related barriers to vaccination, (2) insufficient RSV awareness and information to support informed decision-making, (3) vaccine safety concerns and hesitancy and (4) perception of the maternal RSV vaccine as beneficial and protective. These themes were consistent across sociodemographic groups. Conclusions: Uptake of the maternal vaccine was influenced by barriers to access, informational gaps and perceived safety concerns. Improved vaccine delivery, enhanced awareness and personalised antenatal counselling are essential to increase vaccine uptake. There is an urgent need to address structural inaccessibility and provide tailored antenatal education to address informational gaps. Ongoing qualitative research is crucial to guide targeted public health interventions ahead of future RSV seasons.
Overview
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
The citation lists haven’t been fetched yet
Research works printed but not linked: 21
- 10.1371/journal.ppat.1004016 · DOI
- 10.1016/s0140-6736(22)00478-0 · DOI
- Taylor, 2016, Modelling estimates of the burden of respiratory syncytial virus infection in children in the UK, BMJ Open, 6, 10.1136/bmjopen-2015-009337 · DOI
- Williams, 2024, Clinical Impact of Serious Respiratory Disease in Children Under the Age of 2 Years During the 2021–2022 Bronchiolitis Season in England, Scotland, and Ireland, J Infect Dis, 230, e111, 10.1093/infdis/jiad551 · DOI
- 10.2147/DHPS.S348727 · DOI
- Phillips B , Jackson C , Phillips J . Clesrovimab for the Prevention of Respiratory Syncytial Virus Lower Respiratory Tract Disease in Infants. J Pharm Technol 2025.:87551225251392119. doi:10.1177/87551225251392119 · DOI
- Shoukat, 2023, Cost-effectiveness analysis of nirsevimab and maternal RSVpreF vaccine strategies for prevention of Respiratory Syncytial Virus disease among infants in Canada: a simulation study, Lancet Reg Health Am, 28
- 10.1056/nejmoa2216480 · DOI · Paper page
- 10.1097/inf.0000000000002384 · DOI
- Paulson, 2025, Protecting Against Respiratory Syncytial Virus: An Online Questionnaire Study Exploring UK Parents’ Acceptability of Vaccination in Pregnancy or Monoclonal Antibody Administration for Infants, Pediatr Infect Dis J, 44, S158, 10.1097/INF.0000000000004632 · DOI
- Bussink-Voorend, 2022, A systematic literature review to clarify the concept of vaccine hesitancy, Nat Hum Behav, 6, 1634, 10.1038/s41562-022-01431-6 · DOI
- Larson, 2022, Defining and measuring vaccine hesitancy, Nat Hum Behav, 6, 1609, 10.1038/s41562-022-01484-7 · DOI
- Williams, 2024, Update to: Study Pre-protocol for “BronchStart - The Impact of the COVID-19 Pandemic on the Timing, Age and Severity of Respiratory Syncytial Virus (RSV) Emergency Presentations; a Multi-Centre Prospective Observational Cohort Study”, Wellcome Open Res, 6, 120, 10.12688/wellcomeopenres.16778.3 · DOI
- Betsch, 2018, Beyond confidence: Development of a measure assessing the 5C psychological antecedents of vaccination, PLoS ONE, 13, 10.1371/journal.pone.0208601 · DOI
- 10.1016/j.jbi.2008.08.010 · DOI · Paper page
- Williams, 2025, Maternal views on RSV vaccination during the first season of implementation in England and Scotland, Lancet Infect Dis, 25, e135, 10.1016/S1473-3099(25)00060-X · DOI
- Clarke V , Braun V . Teaching thematic analysis: overcoming challenges and developing strategies for effective learning. Psychologist;26:120–3.
- Treston, 2024, Exploring parental perspectives: Maternal RSV vaccination versus infant RSV monoclonal antibody, Hum Vaccin Immunother, 20, 10.1080/21645515.2024.2341505 · DOI
- Geoghegan, 2022, Understanding Barriers and Facilitators to Maternal Immunization: A Systematic Narrative Synthesis of the Published Literature, Matern Child Health J, 26, 2198, 10.1007/s10995-022-03508-0 · DOI
- Trusinska, 2025, Real-world uptake of nirsevimab, RSV maternal vaccine, and RSV vaccines for older adults: a systematic review and meta-analysis, EClinicalMedicine, 84, 10.1016/j.eclinm.2025.103281 · DOI
- 10.1111/apa.17168 · DOI
Metadata
- Authors
- O’Hagan, S., Williams, T. C., Marlow, R., Drysdale, S. B., Cunningham, S., Groves, H. E., Mpamhanga, C. D., Lyttle, M. D., Hunt, S., Liu, X., Waterfield, T., Roland, D., Iskander, D., & Woolfall, K.
- Venue
- Archives of Disease in Childhood
- Publisher
- BMJ
- Published
- 2026-02-25
- Volume
- 111
- Issue
- 7
- Pages
- 618-624
- ISSN
- 0003-9888
- 1468-2044
- Cited by
- 0
- Language
- en
- Funders
- National Institute for Health and Care Research (NIHR) Health Protection Research Unit in Respiratory Infections, Imperial College London (NIHR200927)
- Wellcome Trust (WT 13600061)
- Respiratory Syncytial Virus Consortium in Europe (116019)
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: Maternal perspectives on the RSV vaccine (Abrysvo): a thematic analysis of survey findings from the first season of implementation in England and Scotland. https://app.cochat.ai/papers/10.1136/archdischild-2025-329427
- The paper
- O’Hagan, S., Williams, T. C., Marlow, R., Drysdale, S. B., Cunningham, S., Groves, H. E., Mpamhanga, C. D., Lyttle, M. D., Hunt, S., Liu, X., Waterfield, T., Roland, D., Iskander, D., & Woolfall, K. (2026). Maternal perspectives on the RSV vaccine (Abrysvo): a thematic analysis of survey findings from the first season of implementation in England and Scotland. Archives of Disease in Childhood. https://doi.org/10.1136/archdischild-2025-329427
